A Phase 2, Open-Label, Single-Arm, Multi-Center Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2019
At a glance
- Drugs AL 101 (Primary)
- Indications Adenoid cystic carcinoma
- Focus Therapeutic Use
- Acronyms ACCURACY
- Sponsors Ayala Pharmaceuticals
- 18 Dec 2018 Status changed from not yet recruiting to recruiting.
- 08 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
- 09 Oct 2018 New trial record